Israel Medical Association Journal

Takotsubo cardiomyopathy (TC) is a temporary and reversible hypokinesia of the left ventricle's apical area of the heart mediating systolic abnormality. This phenomenon resembles myocardial infarction but without coronary artery disease (CAD) [1]. The prevalence is 1.0–2.5% annually. Most of the patients with TC are postmenopausal women [2]. Over-stimulation of the sympathetic system, microvascular and myocardial tissue metabolism abnormality, and coronary artery vasospasm are linked to TC [2]. The criterion of the diagnosis consists of temporary hypokinesis or akinesis in left ventricle segments with or without apical involvement, electrocardiogram (ST-segment elevation and/or T-wave inversion), or significant elevation of serum cardiac troponins and non-existence of pheochromocytoma or myocarditis [3]. The pathognomonic finding of TC during echocardiography is apical ballooning involving the left ventricle. This unique morphology was reported to present in 75% of patients [2,3]. In 25% of patients. The morphology was reported to follow a mid-ventricular ballooning pattern due to mid-LV akinesis with no disturbance of apical and basal contraction [2,3].

Coronavirus disease 2019 (COVID-19) affects different people in different ways. Most infected people develop mild to moderate illness and recover without hospitalization. This case report presents a patient who had difficulty eradicating the corona virus due to being treated with rituximab, which depletes B lymphocytes and therefore disables the production of neutralizing antibodies. The regen-COV-2 antibody cocktail consists of two monoclonal antibodies, casirivimab and imdevimab. This cocktail successfully helped the patient's immune system eradicate the virus without auto specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production. In vitro studies confirm that eradication of the intact the virus. This case report emphases the importance of providing external antiviral antibodies regularly, like the regen-COV-2 antibody cocktail, as post- and even pre- SARS-CoV-2 infection prophylaxis in patients treated with rituximab.